Clinical Trials | Emicizumab in Patients with Acquired Hemophilia A: Multicenter, Single-Arm, Open-Label Clinical Trial

The University of Virginia is conducting a clinical research study for adults ages 18 and over who have been diagnosed with acquired hemophilia A (AHA). The purpose of this study is to assess whether patients diagnosed with acquired hemophilia A (AHA) can safely use emicizumab-kxwh (Hemlibra®) as a prophylactic treatment to reduce or prevent bleeding and to decrease hospital length of stay. Since AHA poses a high risk for bleeding until the antibody is eradicated, prophylactic treatment is important to prevent potential major or life-threatening bleeding. The use of emicizumab for AHA is experimental but is FDA-approved for congenital hemophilia A. If you participate in this study, you will receive two initial loading doses of the study medication (emicizumab) followed by a maintenance dose every week for eleven weeks. A loading dose is a high dose of the medication meant to quickly reach the dose that is needed for treatment in the body. A maintenance dose is the amount of medication needed to keep a desired level of medication in the body. You will be asked to participate in this study for 24 weeks (6 months). You will receive study medication for 12 weeks and be observed for another 12 weeks off study medication. You will receive the study drug through a subcutaneous (under the skin) injection. Study-related procedures that are being done beyond your standard of care will be provided at no cost to you or your insurance. Additional information can be found here: https://clinicaltrials.gov/study/NCT05345197